908 Devices shares jump 20.66% after-hours on strong Q4/FY2025 preliminary results, 20% revenue growth, positive EBITDA.

908 Devices surged 20.66% in after-hours trading following the announcement of strong preliminary 2025 financial results. The company reported full-year revenue of approximately $56 million, reflecting 17% year-over-year growth, and achieved positive Adjusted EBITDA in Q4 2025. Fourth-quarter revenue rose 20% to $17.2 million, driven by robust U.S. state and local sales, international VipIR adoption, and federal/defense contracts. CEO Kevin Knopp highlighted the company’s pivot to a “stronger, simpler, and more profitable” model focused on frontline chemical detection, citing favorable macro trends such as increased funding for opioid crisis mitigation and global defense budgets. While preliminary results remain unaudited and subject to adjustment, the performance exceeded guidance and signaled improved profitability, fueling investor optimism.